Constellation Pharmaceuticals, Inc.
CNST
CNST was delisted on the 14th of July, 2021.
35 hedge funds and large institutions have $73M invested in Constellation Pharmaceuticals, Inc. in 2018 Q3 according to their latest regulatory filings, with 35 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
42.52% more ownership
Funds ownership: 0% → 42.52% (+43%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TG
TRV GP
Boston,
Massachusetts
|
+$28.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$15.4M |
| 3 |
CC
Casdin Capital
New York
|
+$12.5M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$12.1M |
| 5 |
O
OrbiMed
New York
|
+$7.96M |
Top Sellers
CNST Hedge Fund Activity: Q3 2018 in Review
35 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Constellation Pharmaceuticals, Inc. (CNST) for Q3 2018, worth a combined $73M.
Buyers outnumbered sellers: 35 funds opened new CNST positions and 0 closed out — a net gain of 35 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was TRV GP, opening a new position worth an estimated $28.9M.
- 35 institutional investors held Constellation Pharmaceuticals, Inc. (CNST) as of Q3 2018, up from 0 in Q2 2018.
- Funds reported $73M of Constellation Pharmaceuticals, Inc. stock for Q3 2018.
- 35 funds opened new Constellation Pharmaceuticals, Inc. positions in Q3 2018 and 0 closed out, a net change of +35 holders.
- The largest Constellation Pharmaceuticals, Inc. buyer in Q3 2018 was TRV GP, an estimated $28.9M added.
Based on aggregated 13F filings for Q3 2018.